Switzerland buys access to potential Covid-19 treatment drug
The drug could also be administered to risk groups and those in front-line jobs, the Health Office said.
Keystone / Alessandro Crinari
The Swiss government has signed an agreement with a Zurich company for priority access to a drug being developed to treat those severely ill with Covid-19.
This content was published on
1 minute
Keystone-SDA/dos
Português
pt
A Suíça compra acesso ao potencial medicamento de tratamento para o Covid-19
The deal with the Molecular Partners firm gives Switzerland access to the first 200,000 doses of the medicine, as well as up to three million further doses when requested, the Federal Office for Public Health (FOPH) announcedExternal link on Tuesday.
The deal is worth several million francs, the Keystone-SDA news agency reported.
The immunotherapeutic agent, currently in development, is “comparable to mixtures of antibody therapies that are used to neutralise the virus”, the FOPH wrote. If approved, it would mainly be used to treat people already infected with Covid-19, although it could also be administered to risk groups as a prophylactic.
Clinical trials of the drug are planned for Autumn 2020.
The deal is another leg of the government’s anti-coronavirus strategy. It has also put aside CHF300 million ($329 million) for the procurement of a vaccine, and last week announced the pre-purchase of up to 4.5 million doses of a drug being developed by US firm Moderna.
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
This content was published on
The ceasefire in the Iran-Israel war has visibly eased tensions on the financial markets. The SMI, Switzerland's leading stock market index, has risen above the 12,000 point mark again.
This content was published on
Geneva, which is facing several days of very hot weather, has raised its level of vigilance with regard to the risk of forest fires and is issuing an appeal for caution.
Zurich arbitration authority rules in favour of tenants of ‘Sugus Houses’
This content was published on
A conciliation authority says the terminations of 105 flat leases in the so-called "Sugus Houses" in the centre of Zurich were abusive. The tenants therefore do not have to move out - at least for the time being.
This content was published on
Visitors to Switzerland spent CHF19.6 billion ($23.9 billion) last year, a 2.2% rise compared to the previous year, the Federal Statistical Office (FSO) said on Monday.
This content was published on
Despite the current tense economic situation, Swiss consumer sentiment remains positive. The Swiss spent more money in May than the previous year, particularly on restaurant visits and leisure activities, as shown by the latest figures released by PostFinance.
This content was published on
A bear killed four sheep in the Lower Engadine region near Scuol, canton Graubünden, last week. This was the first bear attack on local livestock in four years.
This content was published on
Experts believe that economic development in Switzerland will be weaker in 2026 than the forecasts made three months ago. They have also lowered their predictions for the current year.
This content was published on
Fewer people in Switzerland have a religious affiliation and the proportion who practice their religion regularly is steadily declining, a survey finds.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Government earmarks CHF300 million to secure Covid-19 vaccine
This content was published on
The Swiss government is setting aside funds to procure enough doses of a Covid-19 vaccine for the country’s 8.6 million population.
Switzerland pre-orders 4.5 million doses of Covid-19 vaccine
This content was published on
The Swiss government has signed a deal with US biotech firm Moderna to secure early access to 4.5 million doses of a Covid-19 vaccine currently in development.
This content was published on
It’s the question we all want an answer to: when will there be a vaccine against Covid-19? And how is fair access being negotiated?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.